• Formycon signs an agreement with Bioeq AG and manufacturing partner for resubmission of BLA for FYB201 project (biosimilar- ranibizumab). Bioeq AG is in talks with the US FDA for resubmission supporting manufacturing data in the H2’20
• In Oct 2019- Formycon’s FYB202 (biosimilar- ustekinumab) has completed its P-I trial with its initiation of P-III trial in Q3’20. FYB202 is a co-developed product with Aristo Pharma and Formycon AG while Aristo holds 75.1% and Formycon AG 24.9% and Bioeq will sponsor the trial
• FYB203 (biosimilar- aflibercept) has received approval for neovascular age-related macular degeneration and is expected for P-III trial in mid-20 while Klinge Biopharma GmbH acquires the marketing rights for FYB203 from Santo Holding. Formycon’s FYB206 is in preclinical phase and its IP is established with filling of patent application

Click here to read full press release/ article | Ref: Formycon | Image: Behnace